reported that increased DOT1L triggered epithelial-mesenchymal transition-mediated metastasis from data regarding 410 patients with human hepatocellular carcinoma, but its targeting in vivo was hindered by TAMs-mediated NF-κB signaling, suggesting combined therapy with TAMs depletion or NF-κB inhibition enhanced the efficacy of DOT1L-targeted epigenetic reprogramming (125). Here, DOT1L is linked to hepatocellular carcinoma.